$NMTC

NEUROONE MEDICAL TECHNOLOGIES Corp

CIK:0001500198|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Product revenue	$ 1,973,105	$ 1,696,050	$ 6,727,790	$ 6,356,767
Cost of product revenue	790,496	781,215	2,987,089	2,743,982
Product gross profit	1,182,609	914,835	3,740,701	3,612,785
License revenue				3,000,000
Operating expenses:
Selling, general and administrative	2,181,768	1,618,950	5,986,594	5,602,818
Research and development	1,425,153	1,182,485	4,282,923	3,865,376
Total operating expenses	3,606,921	2,801,435	10,269,517	9,468,194
Loss from operations	(2,424,312)	(1,886,600)	(6,528,816)	(2,855,409)
Fair value change in warrant liability	405,702	319,625	620,171	1,099,421
Financing costs		(9,325)		(334,063)
Other income	12,279	75,432	82,402	103,898
Loss before income taxes	(2,006,331)	(1,500,868)	(5,826,243)	(1,986,153)
Provision for income taxes
Net loss	$ (2,006,331)	$ (1,500,868)	$ (5,826,243)	$ (1,986,153)
Net loss per share (Note 3):
Basic (in Dollars per share)	$ (0.23)	$ (0.19)	$ (0.68)	$ (0.32)
Diluted (in Dollars per share)	$ (0.28)	$ (0.19)	$ (0.75)	$ (0.32)
Number of shares used in per share calculations (Note 3):
Basic (in Shares)	8,661,624	8,100,603	8,511,313	6,141,509
Diluted (in Shares)	8,739,505	8,100,603	8,621,075	6,141,509

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities
Net loss	$ (5,826,243)	$ (1,986,153)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	172,554	197,355
Stock-based compensation	1,054,167	906,048
Valuation adjustments for excess or obsolete inventory	1,000	7,500
Amortization of deferred offering costs		192,647
Non-cash lease expense	88,444	83,187
Fair value change in warrant liability	(620,171)	(1,099,421)
Debt termination costs reclassed to financing activities		141,416
Change in assets and liabilities:
Accounts receivable	165,840	176,636
Inventory	(64,449)	729,952
Prepaid expenses	(177,568)	(16,902)
Accounts payable	(93,078)	(286,960)
Accrued expenses, operating leases and other liabilities	(226,831)	(356,905)
Net cash used in operating activities	(5,526,335)	(1,311,600)
Investing activities
Purchase of property and equipment	(98,929)	(71,135)
Net cash used in investing activities	(98,929)	(71,135)
Financing activities
Proceeds from issuance of common stock attributed to equity financings	1,029,386	9,614,037
Issuance costs related to equity financings	(10,777)	(1,231,873)
Financing costs in connection with debt facility		(297,942)
Deferred issuance costs in connection with at-the-market offering program	(22,920)
Exercise of warrants	174,374
Share repurchases for the payment of employee taxes	(67,585)	(121,846)
Net cash provided by financing activities	1,102,478	7,962,376
Net (decrease) increase in cash and cash equivalents	(4,522,786)	6,579,641
Cash and cash equivalents at beginning of period	6,570,382	1,460,042
Cash and cash equivalents at end of period	2,047,596	8,039,683
Supplemental non-cash financing and investing transactions:
Change in unpaid issuance costs	11,575
Modification of right-of-use asset and associated lease liability		111,898
Purchased property and equipment in accounts payable		7,228
Cashless exercise of warrants	87,188
Reclass of warrant liability to equity upon exercise	342,918
Amortization of deferred offering costs related to equity financings	$ 1,219

Condensed Balance Sheets - USD ($)	Jun. 30, 2026	Sep. 30, 2025
Current assets:
Cash and cash equivalents	$ 2,047,596	$ 6,570,382
Accounts receivable	1,098,965	1,264,805
Inventory, net	2,290,254	2,226,805
Deferred offering costs	33,046	22,920
Prepaid expenses	318,940	141,372
Total current assets	5,788,801	10,226,284
Intangible assets, net	28,210	44,946
Right-of-use asset	166,751	255,195
Property and equipment, net	202,333	259,222
Total assets	6,186,095	10,785,647
Current liabilities:
Accounts payable	905,716	1,010,369
Accrued expenses and other liabilities	1,135,711	1,292,714
Total current liabilities	2,041,427	2,303,083
Warrant liability	303,805	1,266,894
Operating lease liability, long term	73,320	143,148
Total liabilities	2,418,552	3,713,125
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.
Common stock, $0.001 par value; 100,000,000 shares authorized; 8,702,982 and 8,334,336 shares issued and outstanding as of June 30, 2026 and September 30, 2025, respectively.	8,703	8,334
Additional paid–in capital	88,194,870	85,673,975
Accumulated deficit	(84,436,030)	(78,609,787)
Total stockholders’ equity	3,767,543	7,072,522
Total liabilities and stockholders’ equity	$ 6,186,095	$ 10,785,647